Who
Steven W. Lefkowitz
Director
Company insider
Files Form 4 as: Interim Chief Financial Ofcr, CorMedix; Director, Franklin Credit Management; Director, Franklin Credit Holding Corp/de/.
In numbers
- Trades disclosed
- 121
- Buys
- 9
- Sells
- 12
- Bought
- $262K
- Sold
- $986K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 28 Apr 2006
- Last trade
- 26 Jan 2026
- Last filed
- 27 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —30,453 at $0.00 | filing |
| 26 Jan 2026filed 27 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —30,453 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code M | $84K15,000 at $5.63 | filing |
| 12 Jan 2026filed 14 Jan 2026 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code M | $84K15,000 at $5.63 | filing |
| 9 Dec 2025filed 10 Dec 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Sold | $475K40,000 at $11.88 | filing |
| 2 Apr 2025filed 3 Apr 2025 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 2 Apr 2025filed 3 Apr 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code M | $81K20,000 at $4.03 | filing |
| 17 Jan 2025filed 22 Jan 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Mar 2024filed 20 Mar 2024 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 16 Nov 2023filed 17 Nov 2023 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 16 Nov 2023filed 17 Nov 2023 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code M | $34K15,000 at $2.25 | filing |
| 14 Jan 2023filed 18 Jan 2023 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 22 Feb 2022filed 23 Feb 2022 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Jan 2021filed 13 Jan 2021 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 4 Sep 2020filed 9 Sep 2020 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Bought | $14K3,500 at $4.00 | filing |
| 4 Sep 2020filed 9 Sep 2020 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Bought | $8,8162,215 at $3.98 | filing |
| 25 Feb 2020filed 27 Feb 2020 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $84K15,000 at $5.63 | filing |
| 7 Jan 2020filed 27 Feb 2020 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code X | $20K4,500 at $4.50 | filing |
News
Head-To-Head Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus CorMedix (NASDAQ:CRMD)CRMD · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Steven W. Lefkowitz; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.